PPARG and type 2 diabetes mellitus: Taken together, we have provided clear evidence that VSP-51 is a partial agonist for PPARγ that functions as a selectively PPARγ-modulating ligand with improved therapeutic profile compared to Rosi, suggesting that VSP-51 can serve as a promising candidate for the treatment of T2DM and as lead compound for designing newer and better pharmacophores selectively targeting PPARγ.